-
Product Insights
Mild Cognitive Impairment - Drugs In Development, 2024
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol. The Mild...
-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2024
Empower your strategies with our Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function. There are different types of peripheral neuropathy, each affecting specific nerves...
-
Product Insights
Spinal Muscular Atrophy (SMA) - Drugs In Development, 2024
Empower your strategies with our Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024 report and make more profitable business decisions. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms...
-
Product Insights
Neuromuscular Disorders - Drugs In Development, 2024
Empower your strategies with our Neuromuscular Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Neuromuscular disorders are conditions that affect the function of the nerves and muscles in the body. They can cause muscle weakness, fatigue, pain, spasms, and other symptoms. Neuromuscular disorders can be inherited or acquired, and they can affect different parts of the neuromuscular system, such as the peripheral nerves, the skeletal muscles, or the neuromuscular junction. Some examples of neuromuscular disorders are...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2024
Empower your strategies with our Neuromyelitis Optica (Devic's Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Neuromyelitis optica (NMO), also known as Devic's syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems. The Neuromyelitis Optica (Devic's Syndrome) drugs in development market research report provide...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2024
Empower your strategies with our Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it...
-
Product Insights
Tauopathies - Drugs In Development, 2024
Empower your strategies with our Tauopathies – Drugs In Development, 2024 report and make more profitable business decisions. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of tau protein into neurofibrillary or gliofibrillary tangles in the human brain. Tau protein normally stabilizes microtubules, which are essential for intracellular transport and communication. However, when tau becomes hyperphosphorylated or misfolded, it dissociates from microtubules and forms insoluble aggregates that impair neuronal function and survival. Tauopathies can present with various clinical...
-
Product Insights
Friedreich Ataxia - Drugs In Development, 2024
Empower your strategies with our Friedreich Ataxia – Drugs In Development, 2024 report and make more profitable business decisions. Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia drugs in development market research report provide comprehensive information...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Drugs In Development, 2024
Empower your strategies with our Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024 report and make more profitable business decisions. Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They...
-
Product Insights
Insomnia - Drugs In Development, 2024
Empower your strategies with our Insomnia – Drugs In Development, 2024 report and make more profitable business decisions. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress, and shift working. The Insomnia drugs in development market research report provide comprehensive information on the therapeutics under development for Insomnia,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.